An FDA advisory panel on Tuesday voted against using MDMA-assisted therapy to treat PTSD, leading to a setback for potential psychedelic treatments, in today's bite-sized hospital and health industry news from the District of Columbia, Maryland, and New York.
Learn how psychedelic-assisted therapy is disrupting care delivery and generating evidence to change clinical practice.
Create your free account to access 1 resource, including the latest research and webinars.
You have 1 free members-only resource remaining this month.
1 free members-only resources remaining
1 free members-only resources remaining
You've reached your limit of free insights
Never miss out on the latest innovative health care content tailored to you.
You've reached your limit of free insights